To Be Held at COEX, Seoul, from June 7 to 9
'Bio Korea,' a venue for technology exchange in the biohealth industry, will be held at COEX in Gangnam-gu, Seoul, for three days from June 7 to 9. The Korea Health Industry Development Institute announced its plan to support domestic promising pharmaceutical and bio companies in expanding their connections with global corporations and investors, as well as in sharing the latest trends in the biohealth industry such as artificial intelligence (AI), regenerative medicine, and anti-aging, so that they can achieve tangible results through Bio Korea 2025.
Participants are touring booths at 'Bio Korea 2024' held at COEX in Seoul on May 8 last year. Photo by Yonhap News
On April 29, the Institute held a press briefing at Sangyeonjae in Jung-gu, Seoul, to introduce these event plans. Since its launch in 2006, Bio Korea has been recognized as a platform for information and technology exchange in the biohealth industry, laying the foundation for the advancement of Korea's health industry.
Lee Cheolhaeng, Director of the Industrial Promotion Division at the Institute, stated, "We are focusing on business exchange between domestic and international companies," and added, "We plan to ensure that companies can achieve direct results through the business partnering program."
This year's event is themed 'Innovation and Collaboration: Building the Future Together.' Instead of the traditional ribbon-cutting ceremony by dignitaries, this year’s official opening event will be a keynote lecture. Alex Zhavoronkov, CEO of Insilico Medicine, will deliver a lecture on 'AI and Robotics: The Future of Drug Development and Longevity.'
The business partnering program will provide opportunities for business meetings with domestic and international companies and institutions in the biohealth sector. The business partnering area has been expanded by approximately 21% compared to last year. Participants include Johnson & Johnson, Amgen, Boehringer Ingelheim, Pfizer, MSD, Takeda Pharmaceutical, Otsuka Pharmaceutical, Roche, Novo Nordisk, Insilico Medicine, ST Pharm, and SK Bioscience.
The Invest Fair program will cover: ▲Global bio investment trends ▲Investment strategies in the Middle East and Asia ▲Case studies on overcoming investment barriers in Western markets ▲Pitches from innovative domestic bio startups. Major global institutions and investors such as the Ministry of Investment of Saudi Arabia, overseas venture capital firms from the United States and the United Kingdom, JLABS, and the Cambridge Innovation Center (CIC) in the United States will participate in large numbers.
In the exhibition, more than 270 companies from over 20 countries, including those in biotech, digital healthcare, regenerative medicine, and medical devices, will showcase their technologies and products. Domestic participants include Celltrion, ST Pharm, Yuhan Corporation, and ABL Bio. International participants include Johnson & Johnson, Amgen, and Lonza. Notably, this year will feature a 'Rising' zone for promising domestic companies with outstanding technologies. Twenty-four leading Korean companies, such as VPix Medical, Emocog, IPSell, Stemden, and Owl Bio, will present their technologies and items here. Nine countries, including Canada, the Netherlands, and Australia, will also operate national pavilions.
The conference will introduce trends in the biohealth industry and share the future and prospects of new technologies. Fourteen sessions across eleven topics will be held, including new modalities, anti-aging and age reversal, AI-based drug development, and brain-computer interfaces (BCI). The event will highlight global technology trends and explore strategies for Korea to respond amid changing international dynamics.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
